Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALZN NASDAQ:CAPS NYSE:NKGN NASDAQ:PPBT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALZNAlzamend Neuro$2.35-2.5%$2.62$2.06▼$17.73$7.38M-0.3628,603 shs49,490 shsCAPSCapstone Therapeutics$1.28$1.37$0.96▼$16.18$7.14M-0.811.14 million shs96,266 shsNKGNNKGen Biotech$0.13-7.0%$0.18$0.10▼$0.96$5.96M1.191.48 million shs26,440 shsPPBTPurple Biotech$0.57-0.3%$2.05$0.53▼$13.95$1.47M0.7404,418 shs402,305 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALZNAlzamend Neuro0.00%+3.88%+1.26%-22.01%-86.13%CAPSCapstone Therapeutics0.00%+8.47%+3.23%-32.28%+127,999,900.00%NKGNNKGen Biotech0.00%-7.02%-5.36%-56.69%-82.87%PPBTPurple Biotech0.00%-13.56%-75.97%-77.00%+57,049,900.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALZNAlzamend Neuro$2.35-2.5%$2.62$2.06▼$17.73$7.38M-0.3628,603 shs49,490 shsCAPSCapstone Therapeutics$1.28$1.37$0.96▼$16.18$7.14M-0.811.14 million shs96,266 shsNKGNNKGen Biotech$0.13-7.0%$0.18$0.10▼$0.96$5.96M1.191.48 million shs26,440 shsPPBTPurple Biotech$0.57-0.3%$2.05$0.53▼$13.95$1.47M0.7404,418 shs402,305 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALZNAlzamend Neuro0.00%+3.88%+1.26%-22.01%-86.13%CAPSCapstone Therapeutics0.00%+8.47%+3.23%-32.28%+127,999,900.00%NKGNNKGen Biotech0.00%-7.02%-5.36%-56.69%-82.87%PPBTPurple Biotech0.00%-13.56%-75.97%-77.00%+57,049,900.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALZNAlzamend Neuro 3.00Buy$45.001,814.89% UpsideCAPSCapstone Therapeutics 0.00N/AN/AN/ANKGNNKGen Biotech 0.00N/AN/AN/APPBTPurple Biotech 3.00Buy$33.005,699.65% UpsideCurrent Analyst Ratings BreakdownLatest PPBT, NKGN, ALZN, and CAPS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/21/2025ALZNAlzamend NeuroAscendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$180.00 ➝ $45.00(Data available from 9/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALZNAlzamend NeuroN/AN/AN/AN/A$4.95 per shareN/ACAPSCapstone Therapeutics$44.88M0.16N/AN/A($19.40) per share-0.07NKGNNKGen BiotechN/AN/AN/AN/A($2.68) per shareN/APPBTPurple BiotechN/AN/AN/AN/A$12.73 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALZNAlzamend Neuro-$4.51MN/A0.00N/AN/AN/A-151.24%-124.17%N/ACAPSCapstone Therapeutics-$2.56MN/A0.00∞N/AN/AN/AN/AN/ANKGNNKGen Biotech-$82.94M-$2.45N/A∞N/AN/AN/A-479.36%N/APPBTPurple Biotech-$7.24M-$0.42N/AN/AN/AN/A-14.00%-12.52%11/21/2025 (Estimated)Latest PPBT, NKGN, ALZN, and CAPS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/15/2025Q2 2025CAPSCapstone TherapeuticsN/A-$0.13N/A-$0.13N/A$12.85 million8/6/2025Q2 2025PPBTPurple Biotech-$0.21-$0.40-$0.19-$0.40N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALZNAlzamend NeuroN/AN/AN/AN/AN/ACAPSCapstone TherapeuticsN/AN/AN/AN/AN/ANKGNNKGen BiotechN/AN/AN/AN/AN/APPBTPurple BiotechN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALZNAlzamend NeuroN/A6.036.03CAPSCapstone Therapeutics0.220.970.41NKGNNKGen BiotechN/A0.020.02PPBTPurple BiotechN/A2.882.88Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALZNAlzamend Neuro49.61%CAPSCapstone Therapeutics2.55%NKGNNKGen Biotech76.17%PPBTPurple Biotech9.64%Insider OwnershipCompanyInsider OwnershipALZNAlzamend Neuro30.21%CAPSCapstone Therapeutics42.80%NKGNNKGen Biotech10.36%PPBTPurple Biotech2.98%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALZNAlzamend Neuro43.14 million2.19 millionNo DataCAPSCapstone Therapeutics385.58 million3.19 millionN/ANKGNNKGen BiotechN/A44.95 million40.29 millionNot OptionablePPBTPurple Biotech202.59 million2.51 millionOptionablePPBT, NKGN, ALZN, and CAPS HeadlinesRecent News About These CompaniesPurple Biotech receives intention to grant a European patent covering NT219September 10, 2025 | msn.comPurple Biotech Receives Intention to Grant a European Patent Covering NT219 Combinations with Immunotherapies or MEK Inhibitors to Overcome Tumor ResistanceSeptember 10, 2025 | finance.yahoo.comPurple Biotech Announces Closing of Up To $18 Million Public Offering $6 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon the ...September 6, 2025 | markets.businessinsider.comPurple Biotech Announces Closing of Up To $18 Million Public Offering $6 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon the exercise in full of short-term warrantsSeptember 5, 2025 | globenewswire.comPurple Biotech prices 5.99M ADSs at $1.00 in public offeringSeptember 4, 2025 | msn.comPurple Biotech Announces Pricing of Up To $18 Million Public OfferingSeptember 4, 2025 | markets.businessinsider.comPurple Biotech Announces New Data Supporting the Unique Design of CAPTN-3 Tri-Specific Antibody IM1240 in Collaboration with the Icahn School of Medicine at Mount SinaiSeptember 4, 2025 | markets.businessinsider.comPurple Biotech Expands CAPTN-3 Portfolio with Novel Antibody Targeting TROP2September 3, 2025 | msn.comPurple Biotech Expands CAPTN-3 Portfolio with IM1305, a Novel Tri-Specific Antibody Targeting TROP2September 3, 2025 | markets.businessinsider.comPurple Biotech to Participate in the H.C. Wainwright 27th Annual Global Investment ConferenceAugust 27, 2025 | globenewswire.comPurple Biotech Reports Second Quarter 2025 Financial ResultsAugust 6, 2025 | globenewswire.comPurple Biotech CEO Issues Letter to Shareholders Highlighting Pipeline Progress and Clinical Milestones Achieved in First Half of 2025July 23, 2025 | globenewswire.comPurple Biotech Stock Price History - Investing.comJuly 8, 2025 | investing.comPurple Biotech Highlights Significant Advantages of the Novel CAPTN-3 Tri-Specific Antibody Platform at the EACR 2025 Annual CongressJune 23, 2025 | globenewswire.comPurple Biotech Announces Initiation of Phase 2 Study of NT219 in Patients with Head and Neck CancerJune 17, 2025 | finance.yahoo.comPurple Biotech Announces Poster Presentation at EACR 2025 on its Novel CAPTN-3 Tri-Specific Antibody PlatformJune 4, 2025 | finance.yahoo.comH.C. Wainwright Raises Purple Biotech (PPBT) Price Target, Reiterates Buy RatingJune 1, 2025 | msn.comPurple Biotech Ltd.: Purple Biotech Reports First Quarter 2025 Financial ResultsMay 21, 2025 | finanznachrichten.dePurple Biotech Reports First Quarter 2025 Financial ResultsMay 21, 2025 | globenewswire.comPurple Biotech Appoints Shai Lankry as Chief Financial Officer to Drive Strategic Growth and Financial ExcellenceMay 13, 2025 | nasdaq.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePPBT, NKGN, ALZN, and CAPS Company DescriptionsAlzamend Neuro NASDAQ:ALZN$2.35 -0.06 (-2.49%) Closing price 04:00 PM EasternExtended Trading$2.39 +0.04 (+1.70%) As of 04:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.Capstone Therapeutics NASDAQ:CAPS$1.28 0.00 (0.00%) As of 04:00 PM EasternCapstone Therapeutics Corp., a biotechnology company, develops novel peptides and other molecules for helping patients with under-served medical conditions in the United States. It develops Apo E mimetic peptide molecule AEM-28 and its analogs that have completed Phase Ia and Phase Ib/IIa clinical trials for lipoprotein metabolism. The company was formerly known as OrthoLogic Corp. and changed its name to Capstone Therapeutics Corp. in May 2010. Capstone Therapeutics Corp. was founded in 1987 and is headquartered in Tempe, Arizona.NKGen Biotech NYSE:NKGN$0.13 -0.01 (-7.02%) As of 03:36 PM EasternNKGen Biotech, Inc. operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. It develops SNK01, an autologous NK cell therapy; and SNK02, an allogeneic NK cell therapy, which are in Phase 1 clinical trials. The company was founded in 2017 and is based in Santa Ana, California.Purple Biotech NASDAQ:PPBT$0.57 0.00 (-0.26%) Closing price 03:58 PM EasternExtended Trading$0.57 0.00 (0.00%) As of 04:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and IM1240, a multi-valent antibody designed to activate anti-tumoral immune response against 5T4-positive tumors, which is in preclinical stage. The company has collaboration agreement with Bristol Myers Squibb Company to evaluate the combination of CM24 with the PD-1 inhibitor nivolumab in addition to chemotherapy. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company is headquartered in Rehovot, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Commercial Growth Story Is Just Getting Started The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Royal Caribbean's 33% Dividend Hike Signals Deeper Growth MarketBeat Week in Review – 09/08 - 09/12 Adobe’s Rebound Has Room to Run: 25% Upside by Year-End Wall Street Eyes +30% Upside in Synopsys After Huge Earnings Fall Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
